CN102093364B - 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 - Google Patents
作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 Download PDFInfo
- Publication number
- CN102093364B CN102093364B CN201110002776.3A CN201110002776A CN102093364B CN 102093364 B CN102093364 B CN 102093364B CN 201110002776 A CN201110002776 A CN 201110002776A CN 102093364 B CN102093364 B CN 102093364B
- Authority
- CN
- China
- Prior art keywords
- dihydro
- pyrrolo
- mmol
- amino
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C1(*)c2c(NCc3c(*)c(*)c(*)c(*)c3*)nc(Nc3c(*)c(*)c(*)c(*)c3*)nc2NC1 Chemical compound *C1(*)c2c(NCc3c(*)c(*)c(*)c(*)c3*)nc(Nc3c(*)c(*)c(*)c(*)c3*)nc2NC1 0.000 description 2
- YTPJFWHOEXCSPL-UHFFFAOYSA-N CCCNS(c(cccc1)c1Nc1c(CCN2)c2nc(Nc(c(OC)c2)ccc2N2CCOCC2)n1)(=O)=O Chemical compound CCCNS(c(cccc1)c1Nc1c(CCN2)c2nc(Nc(c(OC)c2)ccc2N2CCOCC2)n1)(=O)=O YTPJFWHOEXCSPL-UHFFFAOYSA-N 0.000 description 1
- QKMAMCWZVSKUSK-UHFFFAOYSA-N CCCNS(c1ccccc1N=O)(=O)=O Chemical compound CCCNS(c1ccccc1N=O)(=O)=O QKMAMCWZVSKUSK-UHFFFAOYSA-N 0.000 description 1
- XJPZDTFRRAJBCB-UHFFFAOYSA-N CN(C)S(c(cccc1)c1Nc1c(CCN2Cc(cc3)ccc3OC)c2nc(Nc(ccc(N2CCOCC2)c2)c2OC)n1)(=O)=O Chemical compound CN(C)S(c(cccc1)c1Nc1c(CCN2Cc(cc3)ccc3OC)c2nc(Nc(ccc(N2CCOCC2)c2)c2OC)n1)(=O)=O XJPZDTFRRAJBCB-UHFFFAOYSA-N 0.000 description 1
- GMWQBALBFOYABZ-UHFFFAOYSA-N CNC(c(cccc1)c1Nc1c(CCN2)c2nc(Nc(c2c3OCCO2)ccc3N2CCOCC2)n1)=O Chemical compound CNC(c(cccc1)c1Nc1c(CCN2)c2nc(Nc(c2c3OCCO2)ccc3N2CCOCC2)n1)=O GMWQBALBFOYABZ-UHFFFAOYSA-N 0.000 description 1
- VXGJVAWBHDWLJR-UHFFFAOYSA-N CNC(c(cccc1)c1Nc1c(CCN2)c2nc(Nc(cc2OC)cc(OC)c2OC)n1)=O Chemical compound CNC(c(cccc1)c1Nc1c(CCN2)c2nc(Nc(cc2OC)cc(OC)c2OC)n1)=O VXGJVAWBHDWLJR-UHFFFAOYSA-N 0.000 description 1
- GDCGEFANXTYXCM-UHFFFAOYSA-N CNC(c(cccc1)c1Nc1c(CCN2Cc(cc3)ccc3OC)c2nc(Nc(ccc(N2CCOCC2)c2)c2OC)n1)=O Chemical compound CNC(c(cccc1)c1Nc1c(CCN2Cc(cc3)ccc3OC)c2nc(Nc(ccc(N2CCOCC2)c2)c2OC)n1)=O GDCGEFANXTYXCM-UHFFFAOYSA-N 0.000 description 1
- ZNBHGSBOESHNNE-UHFFFAOYSA-N CNC(c(cccc1)c1Nc1c(CCN2Cc(cc3)ccc3OC)c2nc(Nc2c(cc[n]3CCCN4CCOCC4)c3ccc2)n1)=O Chemical compound CNC(c(cccc1)c1Nc1c(CCN2Cc(cc3)ccc3OC)c2nc(Nc2c(cc[n]3CCCN4CCOCC4)c3ccc2)n1)=O ZNBHGSBOESHNNE-UHFFFAOYSA-N 0.000 description 1
- IYVATGBLYSMJMN-UHFFFAOYSA-N CNC(c1ccc2OCOc2c1Nc1c(CCN2)c2nc(Nc(c(OC)c2)ccc2N2CCOCC2)n1)=O Chemical compound CNC(c1ccc2OCOc2c1Nc1c(CCN2)c2nc(Nc(c(OC)c2)ccc2N2CCOCC2)n1)=O IYVATGBLYSMJMN-UHFFFAOYSA-N 0.000 description 1
- XEFRNCLPPFDWAC-UHFFFAOYSA-N COc1cc(N)cc(OC)c1OC Chemical compound COc1cc(N)cc(OC)c1OC XEFRNCLPPFDWAC-UHFFFAOYSA-N 0.000 description 1
- MDXWDBHTSVUSHC-UHFFFAOYSA-N COc1ccc(CN2c3nc(Nc(ccc(N4CCOCC4)c4)c4OC)nc(Cl)c3CC2)cc1 Chemical compound COc1ccc(CN2c3nc(Nc(ccc(N4CCOCC4)c4)c4OC)nc(Cl)c3CC2)cc1 MDXWDBHTSVUSHC-UHFFFAOYSA-N 0.000 description 1
- ZFDGMMZLXSFNFU-UHFFFAOYSA-N Cc1n[n](C)c(N)c1 Chemical compound Cc1n[n](C)c(N)c1 ZFDGMMZLXSFNFU-UHFFFAOYSA-N 0.000 description 1
- OWLFCTAGTIODMN-UHFFFAOYSA-N Cc1nc(Nc2c(CCN3)c3nc(Nc(c(OC)c3)ccc3N3CCOCC3)n2)ccc1 Chemical compound Cc1nc(Nc2c(CCN3)c3nc(Nc(c(OC)c3)ccc3N3CCOCC3)n2)ccc1 OWLFCTAGTIODMN-UHFFFAOYSA-N 0.000 description 1
- LISVSEDQNDHHNW-UHFFFAOYSA-N Cc1nc(Nc2c(CCN3Cc(cc4)ccc4OC)c3nc(Nc(ccc(N3CCOCC3)c3)c3OC)n2)ccc1 Chemical compound Cc1nc(Nc2c(CCN3Cc(cc4)ccc4OC)c3nc(Nc(ccc(N3CCOCC3)c3)c3OC)n2)ccc1 LISVSEDQNDHHNW-UHFFFAOYSA-N 0.000 description 1
- STZPTBOVPLTDFQ-UHFFFAOYSA-N Nc(c1c(cc2)OCO1)c2C(O)=O Chemical compound Nc(c1c(cc2)OCO1)c2C(O)=O STZPTBOVPLTDFQ-UHFFFAOYSA-N 0.000 description 1
- AENMQFPEVXTSEI-UHFFFAOYSA-N Nc1ccccc1S(NC1CCC1)(=O)=O Chemical compound Nc1ccccc1S(NC1CCC1)(=O)=O AENMQFPEVXTSEI-UHFFFAOYSA-N 0.000 description 1
- GFXIUBNXOUNPOL-UHFFFAOYSA-N Nc1ccccc1S(NC1CCCC1)(=O)=O Chemical compound Nc1ccccc1S(NC1CCCC1)(=O)=O GFXIUBNXOUNPOL-UHFFFAOYSA-N 0.000 description 1
- RSWPJUAYUBRSOA-UHFFFAOYSA-N [O-][N+](c1cccc2c1cc[n]2CCCN1CCOCC1)=O Chemical compound [O-][N+](c1cccc2c1cc[n]2CCCN1CCOCC1)=O RSWPJUAYUBRSOA-UHFFFAOYSA-N 0.000 description 1
- MLDBPBAIRZLOJF-UHFFFAOYSA-N [O-][N+](c1ccccc1S(NC1CCCCC1)(=O)=O)=O Chemical compound [O-][N+](c1ccccc1S(NC1CCCCC1)(=O)=O)=O MLDBPBAIRZLOJF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110002776.3A CN102093364B (zh) | 2011-01-07 | 2011-01-07 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
| PCT/CN2012/070122 WO2012092880A1 (en) | 2011-01-07 | 2012-01-07 | 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS |
| KR1020137020933A KR20130122778A (ko) | 2011-01-07 | 2012-01-07 | FAK/Pyk2 억제제인 2,4-디아미노-6,7-디히드로-5H-피롤로[2,3]피리미딘 유도체 |
| CA2823969A CA2823969C (en) | 2011-01-07 | 2012-01-07 | 2,4-diamino-6,7-dihydro-5h-pyrrolo[2,3]pyrimidine derivatives as fak/pyk2 inhibitors |
| JP2013547804A JP5961628B2 (ja) | 2011-01-07 | 2012-01-07 | ＦＡＫ／Ｐｙｋ２阻害剤である２，４−ジアミノ−６，７−ジヒドロ−５Ｈ−ピロロ［２，３］ピリミジン誘導体 |
| KR1020157037254A KR101811938B1 (ko) | 2011-01-07 | 2012-01-07 | FAK/Pyk2 억제제인 2,4-디아미노-6,7-디히드로-5H-피롤로[2,3]피리미딘 유도체 |
| US13/978,475 US9428508B2 (en) | 2011-01-07 | 2012-01-07 | 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors |
| CN201280004821.1A CN103476776B (zh) | 2011-01-07 | 2012-01-07 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
| AU2012204982A AU2012204982B2 (en) | 2011-01-07 | 2012-01-07 | 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors |
| EP12732345.9A EP2661437B1 (en) | 2011-01-07 | 2012-01-07 | 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110002776.3A CN102093364B (zh) | 2011-01-07 | 2011-01-07 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102093364A CN102093364A (zh) | 2011-06-15 |
| CN102093364B true CN102093364B (zh) | 2015-01-28 |
Family
ID=44126650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110002776.3A Expired - Fee Related CN102093364B (zh) | 2011-01-07 | 2011-01-07 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9428508B2 (enExample) |
| EP (1) | EP2661437B1 (enExample) |
| JP (1) | JP5961628B2 (enExample) |
| KR (2) | KR101811938B1 (enExample) |
| CN (1) | CN102093364B (enExample) |
| AU (1) | AU2012204982B2 (enExample) |
| CA (1) | CA2823969C (enExample) |
| WO (1) | WO2012092880A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102093364B (zh) * | 2011-01-07 | 2015-01-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
| CN103476776B (zh) * | 2011-01-07 | 2016-09-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
| CN108558842B (zh) * | 2014-03-06 | 2021-06-04 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类间变性淋巴瘤激酶抑制剂 |
| WO2016050171A1 (zh) * | 2014-09-29 | 2016-04-07 | 山东轩竹医药科技有限公司 | 多环类间变性淋巴瘤激酶抑制剂 |
| CN109415369B (zh) * | 2016-07-08 | 2021-12-07 | 豪夫迈·罗氏有限公司 | 稠合嘧啶衍生物 |
| CN109311877B (zh) | 2016-07-14 | 2021-05-28 | 豪夫迈·罗氏有限公司 | 稠合嘧啶衍生物 |
| HUE057289T2 (hu) | 2016-08-31 | 2022-05-28 | Jiangsu Hengrui Medicine Co | Oxopikolinamid-származék, annak elõállítási módszere és gyógyszerészeti felhasználása |
| CN107936024B (zh) * | 2016-10-12 | 2021-04-30 | 北京赛林泰医药技术有限公司 | 一种间变性淋巴瘤激酶抑制剂及其制备方法和用途 |
| CN108276410B (zh) * | 2017-01-06 | 2021-12-10 | 首药控股(北京)股份有限公司 | 一种间变性淋巴瘤激酶抑制剂及其制备方法和用途 |
| CN108456210A (zh) * | 2017-02-22 | 2018-08-28 | 北京赛林泰医药技术有限公司 | 一种alk酪氨酸激酶抑制剂的多晶型物及其制备方法 |
| HUE060310T2 (hu) | 2017-04-18 | 2023-02-28 | Shanghai Fochon Pharmaceutical Co Ltd | Apoptosis-indukáló szerek |
| KR101992621B1 (ko) * | 2017-12-07 | 2019-09-27 | 주식회사 온코빅스 | 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물 |
| CN110526915B (zh) * | 2018-05-25 | 2022-02-01 | 首药控股(北京)股份有限公司 | 一种间变性淋巴瘤激酶抑制剂的制备方法 |
| KR102377007B1 (ko) | 2018-09-20 | 2022-03-22 | 한미약품 주식회사 | 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 융합 피리미딘 골격 설폰아마이드 유도체 |
| EP3842435A4 (en) * | 2018-09-20 | 2022-05-11 | Hanmi Pharm. Co., Ltd. | NOVEL SULFONAMIDE DERIVATIVE WITH FUSED PYRIMIDINE FRAMEWORK WITH INHIBITING ACTIVITY ON EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS |
| CN113087709A (zh) * | 2020-01-09 | 2021-07-09 | 沈阳药科大学 | 吡咯并嘧啶类衍生物及其制备方法和应用 |
| US20240067668A1 (en) * | 2020-12-29 | 2024-02-29 | Voronoi Inc. | Heteroaryl derivative compound and use thereof |
| BR112023023075A2 (pt) * | 2021-05-04 | 2024-01-30 | Enalare Therapeutics Inc | Moduladores de canal de potássio de grande condutância, composições dos mesmos, métodos para fabricar os mesmos e métodos de uso dos mesmos |
| CN115368364B (zh) * | 2021-05-19 | 2024-07-16 | 四川大学 | 7H-吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004043367A2 (en) * | 2002-11-06 | 2004-05-27 | Bristol-Myers Squibb Company | Fused heterocyclic compounds and use thereof |
| CN1918158A (zh) * | 2004-02-14 | 2007-02-21 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| CN101594871A (zh) * | 2006-05-26 | 2009-12-02 | 诺瓦提斯公司 | 吡咯并嘧啶化合物及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0782174A (ja) | 1993-09-17 | 1995-03-28 | Takeda Chem Ind Ltd | 抗腫瘍剤 |
| GB0115393D0 (en) * | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| DE102006016426A1 (de) | 2006-04-07 | 2007-10-11 | Merck Patent Gmbh | Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren |
| JP2011518219A (ja) | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ， インコーポレイテッド | タンパク質キナーゼの阻害剤 |
| CN102093364B (zh) * | 2011-01-07 | 2015-01-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
-
2011
- 2011-01-07 CN CN201110002776.3A patent/CN102093364B/zh not_active Expired - Fee Related
-
2012
- 2012-01-07 KR KR1020157037254A patent/KR101811938B1/ko not_active Expired - Fee Related
- 2012-01-07 CA CA2823969A patent/CA2823969C/en not_active Expired - Fee Related
- 2012-01-07 KR KR1020137020933A patent/KR20130122778A/ko not_active Ceased
- 2012-01-07 JP JP2013547804A patent/JP5961628B2/ja not_active Expired - Fee Related
- 2012-01-07 US US13/978,475 patent/US9428508B2/en not_active Expired - Fee Related
- 2012-01-07 AU AU2012204982A patent/AU2012204982B2/en not_active Ceased
- 2012-01-07 EP EP12732345.9A patent/EP2661437B1/en not_active Not-in-force
- 2012-01-07 WO PCT/CN2012/070122 patent/WO2012092880A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004043367A2 (en) * | 2002-11-06 | 2004-05-27 | Bristol-Myers Squibb Company | Fused heterocyclic compounds and use thereof |
| CN1918158A (zh) * | 2004-02-14 | 2007-02-21 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| CN101594871A (zh) * | 2006-05-26 | 2009-12-02 | 诺瓦提斯公司 | 吡咯并嘧啶化合物及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101811938B1 (ko) | 2017-12-22 |
| CN102093364A (zh) | 2011-06-15 |
| JP5961628B2 (ja) | 2016-08-02 |
| KR20130122778A (ko) | 2013-11-08 |
| AU2012204982A1 (en) | 2012-07-12 |
| AU2012204982A8 (en) | 2013-08-29 |
| EP2661437B1 (en) | 2018-11-07 |
| EP2661437A1 (en) | 2013-11-13 |
| CA2823969A1 (en) | 2012-07-12 |
| CA2823969C (en) | 2017-11-28 |
| EP2661437A4 (en) | 2014-07-02 |
| KR20160007677A (ko) | 2016-01-20 |
| WO2012092880A1 (en) | 2012-07-12 |
| JP2014501766A (ja) | 2014-01-23 |
| AU2012204982B2 (en) | 2017-02-23 |
| US20130281438A1 (en) | 2013-10-24 |
| US9428508B2 (en) | 2016-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102093364B (zh) | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 | |
| CN103476776B (zh) | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 | |
| EP3399968B1 (en) | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase | |
| CN106220644B (zh) | 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用 | |
| EP2635587B1 (en) | 6-arylamino pyridone carboxamide as mek inhibitors | |
| CN102388055B (zh) | 咪唑并[2,1-b][1,3,4]噻二唑衍生物 | |
| TW202411220A (zh) | 作為ehmt2抑制劑之胺取代的雜環化合物及其使用方法 | |
| US20120309739A1 (en) | Akt / pkb inhibitors | |
| CN102134218A (zh) | 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂 | |
| WO2016169421A1 (zh) | 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用 | |
| TW202521531A (zh) | 一種靶向泛kras蛋白降解劑的化合物及其應用 | |
| CN103102349B (zh) | 蛋白激酶抑制剂及其组合物和用途 | |
| CN106349228B (zh) | 取代的喹唑啉酮类化合物及其制备方法和用途 | |
| CN110461848A (zh) | 化合物及其在治疗血吸虫病中的用途 | |
| CN108191837A (zh) | PI3Kα/mTOR双激酶抑制剂及其药物组合物和应用 | |
| WO2023109751A1 (zh) | 嘧啶或吡啶类衍生物及其医药用途 | |
| TWI894448B (zh) | Ctla-4小分子降解劑及其應用 | |
| WO2025218778A9 (zh) | 杂环化合物及其作为ret抑制剂的用途 | |
| TW202604908A (zh) | 雜環化合物及其作為ｒｅｔ抑制劑的用途 | |
| WO2023221721A1 (zh) | Shp2抑制剂及其用途 | |
| HK1230186B (zh) | 稠环嘧啶氨基衍生物、其制备方法、中间体、药物组合物及应用 | |
| HK40004229B (zh) | Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂 | |
| NZ615557B2 (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150128 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |